Prostate Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People diagnosed with a specific type of prostate cancer called prostate adenocarcinoma
- People whose cancer has a Gleason score (a measure of how aggressive the cancer looks under a microscope) of no more than 4+4
- People whose cancer volume (the size of the cancerous area) is no more than 1.5 ml if there are up to two areas of cancer, or no more than 3 ml if there is only one area of cancer
- People whose PSA level (a protein in the blood used to help detect prostate cancer) is no higher than 15 ng/dl
- People whose cancer is at a clinical stage of T2c or lower (meaning the cancer has not spread beyond a certain point within the prostate area)
- People who have been assessed as being at a low level of risk during anaesthesia, based on a standard health rating scale known as the ASA score of 2 or less
Who may not be able to join:
- People whose cancer has spread outside the prostate gland itself, as shown on a specialised MRI scan — though cancer that is touching (but not breaking through) the outer layer of the prostate is still permitted (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 63214693
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Overall Survival; Metastasis-Free Survival; Progression-Free Survival; Short-term Clinically Significant Prostate Cancer Recurrence; Intermediate-term Clinically Significant Prostate Cancer Recurrence; Sexual Function; Urinary Function; Bowel Function; Radical Intervention-free Survival; Treatment Failure-free Survival
Can't join this trial?
Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.